Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

A Phase I/II Study of Lenalidomide Plus Obinutuzumab in Relapsed Indolent Lymphoma

Nathan H Fowler, MD, Loretta J. Nastoupil, MD MSc, Collin Chin, MBBS, Paolo Strati, MD, Fredrick B. Hagemeister, MD, Luis E. Fayad, MD, Jason R. Westin, MD, Sheryl G Forbes, Janine Arafat, Lei Feng, MS, Ranjit Nair, MBBS,MD, Raphael E Steiner, MD, Felipe Samaniego, MD, Sattva S Neelapu, MD

Blood (2019) 134 (Supplement_1): 348.

https://doi.org/10.1182/blood-2019-131045

Published: 2019

Journal Articles

Predictive Factors of Response and Survival of Lenalidomide and Rituximab As Initial Treatment of Follicular Lymphoma

Paolo Strati, MD, Ralph J. Johnson, PhD, Sheryl G Forbes, Loretta J. Nastoupil, MD MSc, Felipe Samaniego, MD, Eric Davis, MD, Michael R Green, PhD, Luis Fayad, MD, F. B. Hagemeister, MD, Jason R. Westin, MD, Michael L. Wang, MD, Sattva S Neelapu, MD, Nathan H Fowler, MD

Blood (2019) 134 (Supplement_1): 1533.

https://doi.org/10.1182/blood-2019-129311

Published: 2019

Journal Articles

Safety and Efficacy of Ibrutinib in Combination with Rituximab and Lenalidomide in Previously Untreated Subjects with Follicular and Marginal Zone Lymphoma: An Open Label, Phase II Study

Loretta J. Nastoupil, MD, Hun Ju Lee, MD, F. B. Hagemeister, MD, Jason R. Westin, MD, Felipe Samaniego, MD, Lei Feng, MS, Jiffin John, Sheryl G Forbes, Luis E. Fayad, Michael R Green, PhD, R. Eric Davis, MD, Sattva S. Neelapu, MD, Nathan H. Fowler, MD

Blood (2018) 132 (Supplement 1): 447.

https://doi.org/10.1182/blood-2018-99-113721

Published: 2018

Journal Articles

Seven Year Follow up and Comparison of Dosing Strategies from the Pivotal Phase II Clinical Trial of Lenalidomide Plus Rituximab (R 2 ) in Previously Untreated Follicular Lymphoma

Nathan H. Fowler, MD, Preetesh Jain, MBBS,MDDM,PhD, Loretta J. Nastoupil, MD, F. B. Hagemeister, MD, Sheryl G Forbes, Lore Lagrone, Luis Fayad, MD, Hun Ju Lee, MD, R. Eric Davis, MD, Jason R. Westin, MD, Michael Wang, MD, Sattva S. Neelapu, MD, Felipe Samaniego, MD

Blood (2018) 132 (Supplement 1): 1594.

https://doi.org/10.1182/blood-2018-99-119592

Published: 2018

Journal Articles

Safety and Activity of Lenalidomide and Rituximab in Previously Untreated Marginal Zone Lymphoma: Subgroup Analysis and Long-Term Follow-up of an Open-Label Phase II Trial

Melody R Becnel, MD, Loretta Nastoupil, MD, R. Eric Davis, MD, F. B. Hagemeister, MD, Michelle A. Fanale, MD, Luis Fayad, MD, Jason R. Westin, MD, Michael Wang, BS, Yasuhiro Oki, MD, Linda Claret, Sheryl G Forbes, Lei Feng, MS, Felipe Samaniego, MD, Sattva S. Neelapu, MD, Nathan Fowler, MD

Blood (2017) 130 (Supplement 1): 4040.

https://doi.org/10.1182/blood.V130.Suppl_1.4040.4040

Published: 2017

Journal Articles

Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma

Chan Yoon Cheah, Loretta J. Nastoupil, Sattva S. Neelapu, Sheryl G. Forbes, Yasuhiro Oki, Nathan H. Fowler

Blood (2015) 125 (21): 3357–3359.

https://doi.org/10.1182/blood-2015-03-633156

Published: 2015

NARROW

A Phase I/II Study of Lenalidomide Plus Obinutuzumab in Relapsed Indolent Lymphoma

Predictive Factors of Response and Survival of Lenalidomide and Rituximab As Initial Treatment of Follicular Lymphoma

Safety and Efficacy of Ibrutinib in Combination with Rituximab and Lenalidomide in Previously Untreated Subjects with Follicular and Marginal Zone Lymphoma: An Open Label, Phase II Study

Seven Year Follow up and Comparison of Dosing Strategies from the Pivotal Phase II Clinical Trial of Lenalidomide Plus Rituximab (R 2 ) in Previously Untreated Follicular Lymphoma

Safety and Activity of Lenalidomide and Rituximab in Previously Untreated Marginal Zone Lymphoma: Subgroup Analysis and Long-Term Follow-up of an Open-Label Phase II Trial

Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma

Email alerts

ASH Publications

American Society of Hematology

A Phase I/II Study of Lenalidomide Plus Obinutuzumab in Relapsed Indolent Lymphoma

Predictive Factors of Response and Survival of Lenalidomide and Rituximab As Initial Treatment of Follicular Lymphoma

Safety and Efficacy of Ibrutinib in Combination with Rituximab and Lenalidomide in Previously Untreated Subjects with Follicular and Marginal Zone Lymphoma: An Open Label, Phase II Study

Seven Year Follow up and Comparison of Dosing Strategies from the Pivotal Phase II Clinical Trial of Lenalidomide Plus Rituximab (R 2 ) in Previously Untreated Follicular Lymphoma

Safety and Activity of Lenalidomide and Rituximab in Previously Untreated Marginal Zone Lymphoma: Subgroup Analysis and Long-Term Follow-up of an Open-Label Phase II Trial

Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only